+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Desmopressin Market by End User, Indication, Product Type, Route of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Desmopressin Market by End User, Indication, Product Type, Route of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Desmopressin Market by End User, Indication, Product Type, Route of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083053
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Desmopressin Market grew from USD 1.30 billion in 2024 to USD 1.40 billion in 2025. It is expected to continue growing at a CAGR of 7.09%, reaching USD 1.97 billion by 2030.

Setting the Stage for a New Era in Desmopressin Therapy

Desmopressin has emerged as a cornerstone therapy in managing conditions ranging from bleeding disorders and diabetes insipidus to nocturia, underscoring its vital role in modern medicine. In recent years, clinical advancements and patient-centric innovations have driven the evolution of formulations and delivery mechanisms, expanding both the therapeutic reach and patient convenience of this synthetic vasopressin analogue. As healthcare systems continue to prioritize cost-effective treatments that can be administered across varied care settings, the significance of desmopressin is projected to intensify.

This executive summary delivers a panoramic view of the desmopressin landscape, weaving together regulatory developments, market dynamics, and strategic imperatives. By illuminating key trends and offering actionable insights, the report guides industry leaders and decision-makers through the complex interplay of clinical needs, technological progress, and evolving supply chain realities. Whether you are a pharmaceutical manufacturer, healthcare provider, or investor, understanding these multifaceted drivers is essential for navigating the burgeoning opportunities and challenges in the desmopressin market.

Pioneering Transformations Reshaping the Desmopressin Field

The desmopressin market is undergoing transformative shifts fueled by breakthroughs in formulation science, digital health integration, and patient engagement models. Advances in intranasal sprays and user-friendly subcutaneous delivery devices have unlocked new possibilities for self-administration, reducing the burden on clinical settings while improving adherence and quality of life for patients with central diabetes insipidus and nocturia. Simultaneously, the rise of telemedicine and remote monitoring platforms is enabling real-time tracking of therapeutic outcomes and adverse events, paving the way for data-driven personalization of dosing regimens.

On the regulatory front, accelerated approval pathways and adaptive frameworks are streamlining the introduction of novel desmopressin formulations and biosimilar entrants. This environment has stimulated a surge of collaborations between pharmaceutical innovators and biotechnology firms seeking to optimize molecular stability and enhance route-of-administration flexibility. Cumulatively, these pioneering developments are redefining the competitive landscape, compelling established manufacturers to adopt agile research and development models and digital engagement strategies to maintain leadership.

Assessing the Ripple Effects of US Tariff Changes on Desmopressin

In 2025, the implementation of revised United States tariffs on raw materials and pharmaceutical APIs has introduced significant cost pressures for desmopressin manufacturers and distributors. Increased duties on peptide synthesis components and packaging inputs have led to upward adjustments in production expenses, prompting a ripple effect through the supply chain. In response, leading producers are reevaluating their sourcing strategies, accelerating near-shoring initiatives, and forging new trade partnerships to safeguard margins and ensure uninterrupted access to critical inputs.

These tariff-induced dynamics have reshaped pricing negotiations with payers and healthcare systems, intensifying the focus on value-based contracting and outcomes-driven reimbursement models. Stakeholders are embracing cost-offset analyses that demonstrate the long-term savings associated with reduced hospitalizations and improved patient adherence, thereby mitigating the impact of higher list prices. As the market adapts, companies that proactively optimize supply chain resilience and articulate clear value propositions are best positioned to weather the tariff landscape and secure sustainable growth.

Unveiling Comprehensive Market Segmentation Dynamics

A nuanced understanding of market segmentation is critical for manufacturers and marketers seeking to optimize their desmopressin strategies across diverse channels and patient groups. From the vantage point of end users, demand spans the full continuum of care: clinics deliver specialized oversight, hospitals-both private and public-address acute inpatient needs, while home care settings empower patients through nursing support or self-administration models. Each venue presents distinct procurement processes, training requirements, and patient education imperatives.

Therapeutic indications further shape the demand profile. Bleeding disorders such as Hemophilia A and von Willebrand Disease drive specialized protocols that emphasize high-purity formulations and rigorous quality controls. Central diabetes insipidus and nocturia segments prioritize ease of dosing and flexible administration routes, underscoring the importance of intranasal sprays and oral tablets. Meanwhile, injection formats-whether intravenous or subcutaneous-remain indispensable for acute interventions, necessitating precise cold-chain logistics and clinician training.

Distribution channels also play a decisive role in market access. Health and wellness stores, specialty pharmacies, and supermarkets or hypermarkets anchor the offline retail ecosystem, offering over-the-counter availability in jurisdictions where nicotine agonists meet regulatory criteria. Conversely, direct-to-consumer channels-via company websites or major e-commerce platforms-enable discreet ordering and home delivery, supporting patient autonomy and adherence. By aligning product portfolios with these layered segmentation frameworks, stakeholders can tailor marketing, educational outreach, and supply strategies to capture value across the desmopressin spectrum.

Revealing Regional Variations Driving Desmopressin Adoption

Regional dynamics exert a profound influence on desmopressin adoption, shaping regulatory pathways, reimbursement policies, and patient access. In the Americas, robust pharmaceutical infrastructures and progressive regulatory agencies facilitate rapid market entry for novel formulations, while value-based care initiatives spotlight the long-term cost benefits of home administration and telehealth support. Mexico and Brazil, in particular, are witnessing rising investment in patient assistance programs, broadening access in both urban and rural communities.

Across Europe, the Middle East and Africa, heterogeneity defines pricing and reimbursement landscapes. Western European markets benefit from centralized drug evaluations and well-established rare disease frameworks, whereas emerging economies in the region are progressively updating their regulatory processes to align with international standards. The Gulf Cooperation Council is advancing local manufacturing incentives, reducing dependency on imports, while North African healthcare systems are forging partnerships to enhance desmopressin distribution in remote areas.

In Asia-Pacific, demographic trends and healthcare modernization efforts are driving robust demand. Japan’s aging population emphasizes nocturia management, prompting insurance coverage expansions for intranasal and oral desmopressin products. China’s dual procurement reforms and government-sponsored chronic disease programs are accelerating biosimilar uptake. Meanwhile, India and Southeast Asian nations are leveraging digital health platforms to streamline specialty drug ordering and patient education, amplifying access to self-administration options outside traditional hospital settings.

Spotlight on Leading Players and Emerging Innovators

Leading global pharmaceutical companies continue to dominate the desmopressin space through extensive R&D pipelines and strategic alliances. Large-cap innovators leverage their scale to secure prime regulatory review slots and maintain comprehensive portfolios that span intranasal, injectable, and oral formulations. Concurrently, emerging biotechnology firms are advancing next-generation analogues designed to enhance stability and extend therapeutic windows, positioning themselves as attractive acquisition targets.

Collaborative ventures between industry stalwarts and specialty contract manufacturers have accelerated commercial-scale peptide synthesis, improving cost structures and supply reliability. At the same time, dedicated biosimilar developers are navigating evolving regulatory landscapes to secure approvals in major markets, intensifying competition and driving down pricing. Moreover, technology companies specializing in digital dose monitoring are forging partnerships that embed connectivity into delivery devices, creating integrated care ecosystems that deliver real-time adherence data and support remote clinical decision-making.

Taken together, these multifaceted company strategies underscore the importance of agility, innovation, and cross-sector collaboration in capturing share and sustaining growth amid a dynamic competitive landscape.

Strategic Imperatives to Excel in a Competitive Desmopressin Landscape

Industry leaders should prioritize portfolio diversification to address the full spectrum of patient needs across clinics, hospitals, and home care settings. Designing modular delivery systems that accommodate intravenous, subcutaneous and intranasal routes will enable seamless transitions between acute and maintenance therapy. Investment in digital adherence tools and remote monitoring platforms can differentiate offerings and foster payer partnerships grounded in real-world evidence.

Manufacturers must also refine their supply chains to mitigate tariff volatility and geopolitical disruptions. Diversifying sourcing across multiple regions and securing long-term agreements with peptide synthesis specialists will strengthen resilience. Concurrently, establishing manufacturing footholds in high-growth markets through strategic alliances or joint ventures can reduce lead times and enhance local access.

Finally, forging deeper collaborations with patient advocacy groups and healthcare providers will be instrumental in shaping favorable reimbursement policies and educational initiatives. Transparent communication of clinical and pharmacoeconomic data will drive consensus around value-based contracting, facilitating broader uptake. By embracing these strategic imperatives, companies can navigate market complexities and drive sustainable growth.

Robust Methodology Underpinning the Desmopressin Analysis

This analysis is underpinned by a robust, multi-phase research methodology combining primary and secondary intelligence. In the primary phase, interviews with key opinion leaders in endocrinology, hematology, pharmacy management and patient advocacy provided first-hand insights into clinical practice patterns, formulary decision-making, and emerging unmet needs. These qualitative inputs were supplemented by quantitative surveys of procurement specialists and healthcare administrators to capture market share dynamics across end-user segments and regions.

Secondary research encompassed a comprehensive review of regulatory filings, government databases, clinical trial registries and industry publications. Data triangulation techniques ensured consistency between disparate sources, while rigorous cross-validation with proprietary databases refined the accuracy of segmentation and competitive benchmarking. Market segmentation frameworks were developed to map the interplay of end-user settings, therapeutic indications, product types, routes of administration and distribution channels, enabling granular analysis of demand drivers and growth opportunities.

Finally, all findings underwent critical peer review by therapeutic experts and industry analysts to validate assumptions and reinforce the analytical framework. This systematic approach ensures that the insights presented herein are both evidence-based and strategically actionable.

Synthesizing Insights for Informed Decision Making

The evolving desmopressin market presents a confluence of scientific innovation, regulatory evolution and shifting patient expectations. As novel formulations and connected delivery systems gain traction, the competitive landscape will be defined by those who can seamlessly integrate clinical efficacy with real-world value. The interplay of tariff pressures, segment-specific nuances and regional healthcare dynamics underscores the importance of agility and foresight in strategic planning.

Stakeholders must continuously monitor emerging clinical data, policy updates and technological breakthroughs to anticipate market shifts and adapt their commercial models accordingly. Embracing collaborative ecosystems-whether through co-development agreements, digital health partnerships or patient support programs-will be instrumental in capturing new market segments and enhancing therapeutic outcomes.

Ultimately, the companies that proactively align their portfolios, supply chains and stakeholder engagement strategies with the insights presented in this executive summary will be well positioned to lead in the rapidly evolving desmopressin arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Clinics
    • Home Care Settings
      • Home Care Nursing
      • Self Administration
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Indication
    • Bleeding Disorders
      • Hemophilia A
      • Von Willebrand Disease
    • Central Diabetes Insipidus
    • Nocturia
  • Product Type
    • Injection
      • Intravenous Injection
      • Subcutaneous Injection
    • Intranasal Spray
    • Oral Tablet
  • Route Of Administration
    • Intranasal
    • Intravenous Injection
    • Oral
    • Subcutaneous Injection
  • Distribution Channel
    • Offline Retail
      • Health & Wellness Stores
      • Specialty Stores
      • Supermarkets/Hypermarkets
    • Online Retail
      • Company Websites
      • E-commerce Platforms
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Ferring International Center S.A.
  • Pfizer Inc.
  • Viatris Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Baxter International Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Desmopressin Market, by End User
8.1. Introduction
8.2. Clinics
8.3. Home Care Settings
8.3.1. Home Care Nursing
8.3.2. Self Administration
8.4. Hospitals
8.4.1. Private Hospitals
8.4.2. Public Hospitals
9. Desmopressin Market, by Indication
9.1. Introduction
9.2. Bleeding Disorders
9.2.1. Hemophilia a
9.2.2. Von Willebrand Disease
9.3. Central Diabetes Insipidus
9.4. Nocturia
10. Desmopressin Market, by Product Type
10.1. Introduction
10.2. Injection
10.2.1. Intravenous Injection
10.2.2. Subcutaneous Injection
10.3. Intranasal Spray
10.4. Oral Tablet
11. Desmopressin Market, by Route of Administration
11.1. Introduction
11.2. Intranasal
11.3. Intravenous Injection
11.4. Oral
11.5. Subcutaneous Injection
12. Desmopressin Market, by Distribution Channel
12.1. Introduction
12.2. Offline Retail
12.2.1. Health & Wellness Stores
12.2.2. Specialty Stores
12.2.3. Supermarkets/Hypermarkets
12.3. Online Retail
12.3.1. Company Websites
12.3.2. E-commerce Platforms
13. Americas Desmopressin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Desmopressin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Desmopressin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Ferring International Center S.A.
16.3.2. Pfizer Inc.
16.3.3. Viatris Inc.
16.3.4. Novartis AG
16.3.5. Teva Pharmaceutical Industries Ltd.
16.3.6. Sanofi S.A.
16.3.7. Takeda Pharmaceutical Company Limited
16.3.8. Baxter International Inc.
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.10. Dr. Reddy's Laboratories Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DESMOPRESSIN MARKET MULTI-CURRENCY
FIGURE 2. DESMOPRESSIN MARKET MULTI-LANGUAGE
FIGURE 3. DESMOPRESSIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DESMOPRESSIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DESMOPRESSIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DESMOPRESSIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DESMOPRESSIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DESMOPRESSIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DESMOPRESSIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DESMOPRESSIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DESMOPRESSIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DESMOPRESSIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DESMOPRESSIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DESMOPRESSIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DESMOPRESSIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DESMOPRESSIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DESMOPRESSIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOME CARE NURSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DESMOPRESSIN MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DESMOPRESSIN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DESMOPRESSIN MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DESMOPRESSIN MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DESMOPRESSIN MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DESMOPRESSIN MARKET SIZE, BY NOCTURIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DESMOPRESSIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DESMOPRESSIN MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DESMOPRESSIN MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DESMOPRESSIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DESMOPRESSIN MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DESMOPRESSIN MARKET SIZE, BY HEALTH & WELLNESS STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DESMOPRESSIN MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DESMOPRESSIN MARKET SIZE, BY SUPERMARKETS/HYPERMARKETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DESMOPRESSIN MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DESMOPRESSIN MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DESMOPRESSIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. CANADA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. CANADA DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 71. CANADA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 72. CANADA DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 74. CANADA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 76. CANADA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. CANADA DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 79. CANADA DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 80. MEXICO DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 136. GERMANY DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. GERMANY DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. GERMANY DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 141. GERMANY DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. GERMANY DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 143. GERMANY DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. GERMANY DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. GERMANY DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 146. GERMANY DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. FRANCE DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 154. FRANCE DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. FRANCE DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. FRANCE DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 157. FRANCE DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 169. ITALY DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. ITALY DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 171. ITALY DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 172. ITALY DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. ITALY DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 174. ITALY DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. ITALY DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 176. ITALY DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. ITALY DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. ITALY DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 179. ITALY DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 180. SPAIN DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SPAIN DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. SPAIN DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 185. SPAIN DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. SPAIN DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 187. SPAIN DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SPAIN DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. SPAIN DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 190. SPAIN DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 224. DENMARK DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. DENMARK DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. DENMARK DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. DENMARK DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 231. DENMARK DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. DENMARK DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. DENMARK DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 234. DENMARK DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 246. QATAR DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. QATAR DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 248. QATAR DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. QATAR DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. QATAR DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 251. QATAR DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. QATAR DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 253. QATAR DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. QATAR DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. QATAR DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 256. QATAR DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 257. FINLAND DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. FINLAND DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 259. FINLAND DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. FINLAND DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 262. FINLAND DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. FINLAND DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 264. FINLAND DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. FINLAND DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. FINLAND DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 267. FINLAND DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 290. EGYPT DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. EGYPT DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. EGYPT DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 295. EGYPT DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. EGYPT DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 297. EGYPT DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. EGYPT DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. EGYPT DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 300. EGYPT DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 301. TURKEY DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. TURKEY DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 303. TURKEY DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 305. TURKEY DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 306. TURKEY DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 307. TURKEY DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 308. TURKEY DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. TURKEY DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. TURKEY DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 311. TURKEY DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 323. NORWAY DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. NORWAY DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 325. NORWAY DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. NORWAY DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 327. NORWAY DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 328. NORWAY DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 329. NORWAY DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 330. NORWAY DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. NORWAY DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 332. NORWAY DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 333. NORWAY DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 334. POLAND DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 335. POLAND DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 336. POLAND DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 337. POLAND DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 338. POLAND DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 339. POLAND DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 340. POLAND DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 341. POLAND DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. POLAND DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. POLAND DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 344. POLAND DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 345. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 346. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 347. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 348. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 349. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 350. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 351. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 352. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 353. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 354. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY OFFLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 355. SWITZERLAND DESMOPRESSIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 356. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 357. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 358. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 359. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 360. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 361. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 362. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 363. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 364. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 365.

Companies Mentioned

The companies profiled in this Desmopressin market report include:
  • Ferring International Center S.A.
  • Pfizer Inc.
  • Viatris Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Baxter International Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.97 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Desmopressin - Global Strategic Business Report - Product Image

Desmopressin - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Desmopressin (DDAVP) Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Desmopressin (DDAVP) Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 96 Pages
  • Global
From
Antidiuretic Drugs - Global Strategic Business Report - Product Image

Antidiuretic Drugs - Global Strategic Business Report

  • Report
  • 178 Pages
  • Global
From
Enuresis Treatment Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Enuresis Treatment Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 114 Pages
  • Global
From

About the Desmopressin Market

Desmopressin is a synthetic analogue of the natural hormone arginine vasopressin, used to treat endocrine and metabolic disorders. It is used to treat diabetes insipidus, a condition in which the body does not produce enough antidiuretic hormone, resulting in excessive urination and dehydration. It is also used to treat nocturnal enuresis, or bedwetting, in children. Desmopressin is available in tablet, intranasal spray, and injection forms. Desmopressin is also used to treat von Willebrand disease, a bleeding disorder caused by a deficiency of von Willebrand factor. It is used to increase the level of von Willebrand factor in the blood, allowing it to clot more effectively. Desmopressin is a widely used drug in the endocrine and metabolic disorders market. It is available from many pharmaceutical companies, including Novartis, Pfizer, and Merck. It is also available in generic forms from many generic drug manufacturers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.